1. Home
  2. REGN vs BX Comparison

REGN vs BX Comparison

Compare REGN & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$773.14

Market Cap

79.4B

Sector

Health Care

ML Signal

N/A

Logo Blackstone Inc.

BX

Blackstone Inc.

N/A

Current Price

$110.18

Market Cap

116.4B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
REGN
BX
Founded
1988
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
79.4B
116.4B
IPO Year
1995
2007

Fundamental Metrics

Financial Performance
Metric
REGN
BX
Price
$773.14
$110.18
Analyst Decision
Buy
Buy
Analyst Count
24
16
Target Price
$819.54
$169.50
AVG Volume (30 Days)
617.3K
8.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.49%
4.29%
EPS Growth
8.19
6.91
EPS
41.48
3.87
Revenue
$5,872,227,000.00
$14,450,265,000.00
Revenue This Year
$11.69
$14.94
Revenue Next Year
$10.06
$21.75
P/E Ratio
$18.31
$28.39
Revenue Growth
20.82
9.22
52 Week Low
$476.49
$105.09
52 Week High
$821.11
$190.09

Technical Indicators

Market Signals
Indicator
REGN
BX
Relative Strength Index (RSI) 49.70 31.61
Support Level $740.39 $105.09
Resistance Level $788.69 $165.14
Average True Range (ATR) 21.16 5.09
MACD -1.91 0.06
Stochastic Oscillator 54.56 20.94

Price Performance

Historical Comparison
REGN
BX

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About BX Blackstone Inc.

Blackstone is the world's largest alternative-asset manager with $1.242 trillion in total asset under management, including $906.2 billion in fee-earning assets under management, at the end of September 2025. The company operates with scale in each of its major product lines: private equity (26% of fee-earning AUM and 33% of base management fees), real estate/real assets (31% and 35%), private credit (34% and 25%), and other alternatives (9% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).

Share on Social Networks: